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Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a 
radiosensitizer for concurrent chemoradiation in the 
treatment of uterine cervical cancer
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Objective: To evaluate the acute toxicity of rofecoxib during concurrent use with cisplatin-based chemoradiotherapy 
(CCRT) in patients with cervical cancer.
Methods: We evaluated 67 FIGO stage IB2-IVA cervical cancer patients treated with CCRT between June 2002 and July 
2004. The study group included patients who received rofecoxib (N=30) and the control group included patients who 
received CCRT only (N=37). The patients’ medical records were retrospectively reviewed for patient characteristics, 
toxicity related to CCRT and treatment results.
Results: There were no significant differences in toxicity between the two groups. The most common acute grade 3/4 
toxicity was neutropenia (13.3% in the study group and 21.6% in the control group). Grade 3/4 late toxicity was 
observed in 2 (6.6%) patients in the study group and 3 (8.1%) in the control group. There was no treatment-related 
deaths in either group. Six (20.0%) patients in the study group had treatment failure. In the control group, 6 (16.2%) 
patients experienced treatment failure. Progression-free and overall survival was 55.8±4.2 and 59.0±2.8 months, 
respectively, in the study group, and 69.7±4.3 and 71.6±3.6 months, respectively, in the control group. There were no 
differences in progression-free and overall survival between the 2 groups.
Conclusion: Our data indicate that rofecoxib, at a dose of 25 mg twice daily, has acceptable acute toxicity as a 
radiosensitizer during CCRT. Although rofecoxib was not efficacious as a radiosensitizer in the present study, the 
benefit of rofecoxib as a radiosensitizer should be further evaluated in a prospective study.
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INTRODUCTION
Uterine cervical cancer is the second most common gyneco-
logic malignancy worldwide. In Korea, cervical cancer is the 
third leading gynecologic cancer and it accounts for 9.8% of 
newly diagnosed cancer in Korean women, with approx-
imately 4,500 new cases diagnosed in 2002.1 Radiotherapy is 
one of the major treatment modalities for cervical cancer. In 
particular, concurrent chemoradiotherapy (CCRT) has im-
proved the overall survival rate in women with locally ad-
vanced cervical cancer.2-6 However, one-third of patients with 
locally advanced cervical cancer still experience treatment 
failure within 2 years.4 Therefore, there is an urgent need to 
improve the survival rate of patients with locally advanced 
cervical cancer.
Cyclooxygenase (COX)-2 is one of the promising molecules 
that may improve the survival rate of patients with cervical 
cancer. COX is a key enzyme that catalyzes the conversion of 
arachidonic acids into prostaglandins, which are involved in 
carcinogenesis. The 2 isoforms of cyclooxygenase, COX-1 and 
-2, work in a similar fashion and share 61% homology at the 
amino acid level. Under many circumstances, COX-1 is con-
stitutively expressed whereas COX-2 can undergo rapid in-
duction through various stimuli.7 COX-2 expression has an 
important role in tumor angiogenesis, apoptotic inhibition, 
and tumor cell proliferation.8-10 COX-2 expression is known 
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Fig. 1. Flow diagram for patient 
selection. 
CCRT: concurrent chemoradiotherapy.
to be associated with various malignancies, including cervical 
cancer.11-13 Additionally, numerous studies have reported that 
COX-2 overexpression is associated with poor prognosis and 
an unfavorable outcome in uterine cervical cancer.3,14,15 
Therefore, COX-2 is considered a target molecule and a COX-2 
inhibitor may be a candidate agent for the treatment and pre-
vention of cervical cancer. 
Several COX-2 inhibitors, such as rofecoxib, celecoxib, val-
decoxib and parecoxib, have been developed and phase II clinical 
trials for celecoxib have already been completed. However, 
there are few studies on the efficacy and toxicity of other 
COX-2 inhibitors, such as rofecoxib, in the treatment of cer-
vical cancer. Merck & Co. (Whitehouse Station, NJ, USA) 
withdrew rofecoxib from the market because of concerns 
about the increased risk of cardiovascular disease. It is diffi-
cult to prospectively evaluate the acute toxicity and efficacy of 
rofecoxib as a radiosensitizer for the treatment of cervix 
cancer. Therefore, we performed this study to evaluate the 
acute toxicity of rofecoxib when it is used as an adjuvant agent 
to improve radiosensitivity for CCRT in the primary treat-
ment of cervical cancer.
MATERIALS AND METHODS
1. Eligibility
For this study, we enrolled patients with FIGO stage 
IB2-IVA cervical cancer who were treated with CCRT between 
June 2002 and July 2004 at the Department of Obstetrics and 
Gynecology, Yonsei University Health System. Patient demo-
graphic data, treatment results and treatment related compli-
cations were retrospectively reviewed from the patients’ med-
ical records. Clinical staging of uterine cervical cancer for each 
patient was based on the FIGO classification system. The 
medical records of 188 consecutive patients who were diag-
nosed with cervical cancer and treated at our institution from 
June 2002 to July 2004 were initially reviewed. Fig. 1 summa-
rizes the distribution of the patients. Of the 188 patients, we 
included 67 patients with stage IB2-IVA cervical cancer who 
received concurrent chemoradiotherapy. Patients received 
CCRT if they met the following criteria: 1) a performance sta-
tus of 2 or less on the Eastern Cooperative Oncology Group 
(ECOG) scale; 2) adequate bone marrow, hepatic and renal 
functions defined as white blood cells ≥ 4,000 /mm3, abso-
lute neutrophil count (ANC) ≥ 1,500 /mm3, platelet count ≥ 
100,000 /mm3, hemoglobin ≥ 8.0 g/dl, serum bilirubin ≤ 1.5 
mg/dl, alanine aminotransferase/aspartate aminotransferase 
≤ 2.5 times the upper limit of normal and serum creatinine ≤ 
1.5 mg/dl; and 3) written informed consent and agreement to 
undergo rofecoxib treatment. Patients who had medical ill-
ness preventing the use of rofecoxib were considered in-
eligible for rofecoxib treatment. Such medical illness included 
the following: previous psychiatric illness, previous hyper-
sensitivity to COX-2 inhibitor, known human immunodeficiency 
virus infection, active gastrointestinal ulcers or inflammatory 
bowel disease.
The pretreatment evaluation included a pelvic examination, 
common laboratory tests, chest X-ray, magnetic resonance 
imaging (MRI) of the pelvis at least to the level of the renal 
vessels, cystoscopy, intravenous pyelogram and sigmoido-
scopy. Lymph node metastasis was evaluated using MRI with-
out pathologic evaluation. Lymph nodes larger than 1 cm in 
the short-axis diameter were considered metastasis. This 
study was approved by the Institutional Review Board of 
Yonsei University College of Medicine.
2. Radiation therapy
Radiotherapy was delivered with a combination of external 
irradiation and high-dose rate intracavitary radiation by a re-
mote afterloading system using iridium192 sources (Gamma- 
Med II). External whole-pelvis irradiation was performed 
with a dose of 1.8 Gy per fraction 5 times per week to a midline 
dose of 27.0-36.0 Gy. This was followed by high-dose rate in-
tracavitary radiation with 6 insertions (twice per week) with 
a fractional dose of 5.0 Gy to a total dose of 30.0 Gy at point 
A. After high-dose rate intracavitary radiation, patients re-
ceived a second course of external irradiation with central 
shielding up to a total external dose of 45.0-50.4 Gy. Parametrial 
or pelvic side wall boost with central shielding was used for 
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patients with suspected residual parametrial disease after 
planned external irradiation and brachytherapy. The total 
dose to point A and point B was usually between 75 Gy and 90 
Gy and 45 to 65 Gy, respectively, depending on the extent of 
parametrial disease.
3. Chemotherapy
During radiotherapy, cisplatin was given intravenously once 
a week at a dose of 40 mg/m2 of body surface area (BSA) with 
the total dose not exceeding 70 mg per week. In addition, pa-
tients in the study group were given rofecoxib as a radio-
sensitizer during chemoradiotherapy. Rofecoxib (Vioxx®, 
Merck & Co., Inc.) was started on day 1 of radiotherapy and 
continued daily during chemoradiotherapy (25 mg per os 
b.i.d., total 50 mg daily).
4. Monitoring of toxicity, treatment response and survival
For chemotherapy, all patients were admitted to the hospital 
for 2 to 3 days. A 24-hour urine-creatinine clearance, pelvic 
exam, colposcopy, complete blood count with differential and 
platelet count, routine chemistry, chest X-ray, electrocardio-
gram and blood pressure measurement were taken weekly be-
fore each cycle of chemotherapy was started. Adverse events 
and severity were recorded according to the Common Toxicity 
Criteria version 2.0 (CTC ver. 2.0). Acute toxicities were de-
fined as those that developed during CCRT or within 90 days 
after completion. Late toxicities were those occurring 90 days 
after completion of CCRT. If the patient experienced grade 3 
or 4 gastrointestinal, renal, cardiac, pulmonary, hepatic or 
neurologic toxicity, chemotherapy was withheld until the tox-
icity had resolved to grade 0-2.
5. Treatment response and patient survival
Objective responses were confirmed 6 weeks after the cri-
teria for response were first met. Patients underwent MRI, 
colposcopy and pelvic exam after treatment to determine 
treatment response. The Response Evaluation Criteria in 
Solid Tumors (RECIST) guidelines were used to determine 
overall response. Complete response (CR) was defined as the 
disappearance of all target lesions; partial response (PR), at 
least a 30% decrease in the sum of longest diameter of target 
lesions; progressive disease (PD), at least a 20% increase in 
the sum of the longest diameter of target lesions; and stable 
disease (SD), neither sufficient shrinkage to qualify for PR nor 
increase to qualify for PD. Local treatment failure was defined 
as the persistence of local disease or local recurrence, and re-
gional treatment failure was defined as the persistence, ap-
pearance or recurrence of regional nodal disease. The fol-
low-up schedule was every month for the first 3 months, every 
3 months for the first year, and every 6 months thereafter. 
Progression-free survival was determined from the date of the 
end of treatment to the date of disease progression. Overall 
survival was determined from the date of the end of treatment 
until death or the last date that the patient was reported alive. 
We investigated the cause of death and survival in 16 patients 
who were not followed up by telephone survey and data from 
the Korea National Cancer Information Center. Six patients 
were followed by telephone and the others were followed by 
data from the Korea National Cancer Information Center.
6. Statistical analysis
Although this was a retrospective study, a sample size was 
calculated with grade 3-4 acute toxicities including hemato-
logic toxicities, vomiting or diarrhea, cardiac, pulmonary, 
hepatic and neurologic toxicity as the primary endpoint. 
Based on the acute toxicities data from Kim et al.,16 26% of pa-
tients who received CCRT with a weekly cisplatin regimen ex-
perienced grade 3-4 toxicities. Assuming 25% of the acute 
toxicity is considered tolerable, 45% or above of acute tox-
icities are considered excessive. A study design with a 1:1 allo-
cation of study:control group with a significance level of 0.10 
and a 2-sided, 2-sample t-test with a power of 80% would re-
quire 28 patient in each group to demonstrate a 20% ag-
gravation in grade 3-4 acute toxicities. Statistical analysis was 
performed using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). 
Differences in clinicopathologic parameters, toxicity and pat-
tern of treatment failure were evaluated by independent T 
test, Pearson chi-square test and Fisher’s exact test. To esti-
mate overall and progression-free survival, the Kaplan-Meier 
method was used. Survival difference was analyzed using a 
log-rank test. A difference was considered significant when 
the p-value was less than 0.05.
RESULTS
1. Patient characteristics
Between June 2002 and July 2004, 67 patients with locally 
advanced cervical cancer were treated with CCRT. Thirty of 67 
patients received rofecoxib during chemoradiotherapy and 
were assigned to the study group. The control group consisted 
of 37 patients who received only CCRT. The median age of all 
patients was 50.6 years (range, 29 to 80 years). The median 
tumor size was 4.1 cm (range, 1.5 to 7.5 cm). Patient charac-
teristics are summarized in Table 1. There were no statisti-
cally significant differences in clinicopathologic parameters 
between the two groups.
2. Treatment compliance
Seven (22.2%) patients failed to complete the planned treat-
ment of rofecoxib. Four patients discontinued rofecoxib due 
to gastrointestinal toxicity such as gastritis, which did not af-
fect the chemotherapy schedule for the patients. The others 
showed poor compliance with daily rofecoxib treatment. 
However, they completed the planned treatment with CCRT. 
The median treatment duration of rofecoxib in those patients 
was 35.5 days. Four patients in the study group could not 
complete their planned weekly cisplatin chemotherapy. Among 
them, 2 had grade 3/4 neutropenia and 1 experienced severe 
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Table 2. Acute toxicities of concurrent chemoradiotherapy
Acute toxicities
Study group (N=30) Control group (N=37)
p-valueGrade (no.) Grade (no.)
1 2 3 4 1 2 3 4
ECOG performance status
Hematologic
  Neutropenia
Anemia
Thrombocytopenia
Cardiovascular (EKG)
Hepatic (SGOT/SGPT)
Renal (creatinine)
Gastrointestinal (vomiting/diarrhea)
21
 
9
13
14
2
9
1
3
7
 
3
13
1
0
0
0
  3
1
 
2
1
1
0
0
0
0
0
 
0
0
0
0
0
0
0
21
 
8
24
14
4
11
1
6
9
 
10
10
1
1
3
0
   2
3
 
3
1
1
0
2
0
0
1
 
1
0
2
0
0
0
0
NS
NS
 
 
 
NS
NS
NS
NS
ECOG: Eastern Cooperative Oncology Group, EKG: electrocardiography, SGOT/SGPT: serum glutamic oxaloacetic transaminase/serum gluta-
mic pyruvic transaminase.
Table 1. Patient characteristics
Characteristics
Study group
(N=30)
Control group
(N=37)
p-value
no. (%)
Age
Median, yr (range)
Stage
IB2
IIA
IIB
IIIA
IIIB
IVA
Cell type
Squamous cell carcinoma
Adenocarcinoma
Adenosquamous cell
 carcinoma
Small cell carcinoma
ECOG performance status
0
1
2
Lymph node involvement
Pelvic lymph node
Paraaortic lymph node
Tumor size 
Median, cm (range)
Median treatment duration 
of rofecoxib, days (range)
No. of completed planned 
chemotherapy cases
 
50.3 (31-80)
 
5 (16.7)
3 (10.0)
18 (60.0)
1 (3.3)
2 (6.7)
1 (3.3)
 
25 (83.3)
4 (13.3)
0 (0)
1 (3.3) 
11 (36.7)
18 (60.0)
1 (3.3)
   
9 (30.0) 
1 (3.3)
 
4.1 (1.5-6.5)
57 (11-170)
26 (86.7) 
 
50.7 (29-75)
 
4 (10.8)
3 (8.1)
25 (67.6)
1 (2.7)
4 (10.8)
0 (0)
 
31 (83.8)
3 (8.1)
1 (2.7)
2 (5.4)
 
14 (37.8)
20 (54.1)
3 (8.1)
13 (35.1)
2 (5.4)
 
  4.1 (2.0-7.5)
30 (81.1)
NS
NS
 
 
 
 
 
 
NS
 
 
 
  
NS
 
 
 
NS
 
 
NS
 
NS
ECOG: Eastern Cooperative Oncology Group.
anemia. The other patient was an 80-year-old woman with an 
ECOG performance status of 3 during chemotherapy. After 2 
cycles of chemotherapy, she refused additional treatment. 
Seven patients in the control group could not complete their 
planned chemotherapy. Four patients stopped chemotherapy 
due to grade 3/4 hematologic toxicity and 1 due to liver 
toxicity. One patient experienced systemic hypersensitivity 
reactions including skin rash, hypotension and dyspnea after 
the third cycle, and another was diagnosed with renal cell car-
cinoma in the fifth cycle of CCRT. Those two patients also 
stopped receiving chemotherapy.
3. Toxicity
All patients were examined for acute toxicities. Table 2 dem-
onstrates treatment-related acute toxicities. There was no 
treatment-related death in either group. The most common 
grade 3 and 4 toxicities were hematologic. However, all pa-
tients who experienced severe hematologic toxicities recov-
ered with supportive treatment. All cardiovascular complica-
tions observed in the study group were nonspecific T wave 
changes on electrocardiography. No patient in the study 
group developed myocardial infarction or angina pectoris. 
There were no significant differences in the frequency of acute 
toxicities between the two groups. Three patients in the study 
group and 6 in the control group stopped chemotherapy due 
to acute toxicities.
In the study group, 1 patient who showed persistent disease 
developed a vesicovaginal fistula 1 year after CCRT. There 
was a case of radiation proctitis combined with hematochezia 
requiring transfusion. In the control group, 3 cases of late tox-
icity were noted. Among these, there were 2 cases of radiation 
proctitis and 1 of small bowel perforation.
4. Treatment response and patient survival
In the study group, 6 patients showed treatment failure. The 
treatment failure pattern distribution included 3 local failures 
and 3 regional failures. Two patients had SD and died at 14 
and 29 months, respectively, after completion of CCRT. 
Another patient who was diagnosed with FIGO stage IVA cer-
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Fig. 2. Progression-free (A) and overall survival (B) with rofecoxib treatment. There were no differences in progression-free and overall sur-
vival between the 2 groups (p=0.46 and p=0.30, respectively).
Table 3. Demographics of patients who had treatment failure
No. Age FIGO stage Treatment Treatment result Recurrence site Overall survival (month)
1 47 IIB CCRT+Vioxx SD - 29 
2 46 IIIA CCRT+Vioxx SD - 14 
3 46 IVA CCRT+Vioxx PR - 35
4 50 IIB CCRT+Vioxx Recurrence Left iliac LN 44
5 46 IIIB CCRT+Vioxx Recurrence Left supraclavicular LN 37
6 50 IIB CCRT+Vioxx Recurrence Left iliac LN 40
7 48 IIB CCRT SD - 11
8 56 IIB CCRT SD - 8
9 47 IIB CCRT PD - 3
10 36 IB2 CCRT Recurrence Vaginal vault 79
11 50 IIB CCRT Recurrence Left iliac LN 51
12 50 IIB CCRT Recurrence Left iliac LN 48
CCRT: concurrent chemoradiotherapy, SD: stable disease, PR: partial response, LN: lymph node.
vical cancer showed partial response and died at 35 months. 
Other patients developed recurrent cervical cancer within 24 
months. Two patients recurred in the left iliac lymph node and 
another in the left supraclavicular lymph node. Overall surviv-
al of those 3 patients was 44, 40 and 37 months, respectively. 
In addition, 3 patients developed other malignancies, such as 
non-small cell lung cancer, cholangiocellular carcinoma and 
pancreatic cancer, and died at 36, 34 and 35 months during 
follow-up, respectively. 
In the control group, there was 1 case of PD, 2 of SD and 3 of 
recurrence. Six cases of treatment failures included 4 cases of 
local failures and 2 cases of regional failures. Two patients re-
curred in the iliac lymph nodes and 1 in the vaginal vault. All 
6 patients who showed treatment failure died. In addition, 2 
patients developed other malignancies during follow-up; one 
patient developed lung cancer after 69 months of follow-up 
and died at 77 months, and the other was diagnosed with renal 
cell carcinoma during the fifth cycle of CCRT and was cured 
after surgery (Table 3). All patients who died of secondary ma-
lignancy in this study were in complete remission of cervical 
cancer.
The median follow-up duration was 52.9±13.4 months in 
the study group and 63.9±19.3 months in the control group. 
Progression-free survival was 55.8±4.2 months in the study 
group and 69.7±4.3 months in the control group (Fig. 2A). 
Overall survival was 59.0±2.8 months in the study group and 
71.6±3.6 months in the control group (Fig. 2B). There were 
no differences in progression-free and overall survival be-
tween the 2 groups (p=0.46 and p=0.30, respectively).
DISCUSSION
Based on the results of 5 randomized trials, CCRT is consid-
ered to be the primary treatment for locally advanced cervical 
cancer.2-6 Weekly cisplatin alone and cisplatin plus 5-fluo-
rouracil were effective regimens for CCRT in these trials. In 
the present study, cisplatin was given intravenously once a 
week at a dose of 40 mg/m2 of body surface area (BSA), with 
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the total dose not exceeding 70 mg per week during radio-
therapy. Two of the randomized studies reported acute toxi-
cities related to CCRT using weekly cisplatin. Keys et al. in-
dicated that 64 of 183 patients in the CCRT group had grade 
3/4 adverse effects that consisted of hematologic (21.3%) and 
gastrointestinal (GI) toxicities (14.2%). Grade 3/4 leucope-
nia and GI toxicities were also reported by Rose et al. in 23% 
and 12 % of cases, respectively.4
Our data revealed that grade 2 GI toxicities in the study and 
control groups were 16.6% and 16.2%, respectively. Grade 
3/4 neutropenia was observed in 13.3% of cases in the study 
group and 21.6% of cases in the control group. There were no 
significant differences in acute toxicities between the study 
and control groups. The daily dosage of rofecoxib in the pres-
ent study was 50 mg, which is the typical dose for other dis-
eases such as arthritis and primary dysmenorrhea. These re-
sults related to toxicities were comparable to those of other 
randomized trials, indicating that a conventional dose of rofe-
coxib does not elevate acute toxicities related to CCRT.
Although there is no study with which to compare our data 
on the toxicity of rofecoxib during radiotherapy or CCRT, two 
clinical phase II trials revealed toxicities of celecoxib com-
bined with CCRT. Gaffney et al.17 reported a significant rate of 
acute GI toxicity in 43% (33/77) of patients in the RTOG 0128 
study using celecoxib. The most frequently observed grade 3 
and 4 toxicity was hematologic toxicity (40/77). Twenty pa-
tients showed grade 3 and 4 leucopenia. There were no car-
diovascular complications related to the COX-2 inhibitor. 
Twenty percent of patients discontinued celecoxib due to 
toxicity. The author concluded that celecoxib at 400 mg twice 
daily together with CCRT produces a high incidence of acute 
toxicities. Another phase I-II trial using celecoxib as a radio-
sensitizer was performed by Herrera et al.18 The author dem-
onstrated that the most common acute grade 3/4 toxicities 
were hematologic (4/31) and gastrointestinal (5/31). Three 
of 31 patients developed recto-vaginal fistulas as late com-
plications. Performing interim analysis of acute and late tox-
icities, the authors found that celecoxib at 800 mg/day did not 
elevate acute toxicities, but did increase late toxicities. As a 
result, the celecoxib dose was reduced to 300 mg twice daily. 
Combining the results of these studies, 300 mg twice daily 
dose is considered to be a safer dose for a radiosensitizer in the 
treatment of locally advanced cervical cancer. 
Our data on toxicities was superior to that of the RTOG 0128 
study. Our lower rates of acute GI and hematologic toxicities 
might be due to differences in the disease stage of enrolled pa-
tients and chemotherapy regimens. The chemotherapy regi-
men used by Gaffney et al.17 was cisplatin at 75 mg/m2 to a 
maximal dose of 150 mg with 5-fluorouracil. A prospective 
randomized study, which was conducted to compare monthly 
fluorouracil plus cisplatin and weekly cisplatin-based CCRT 
for cervical cancer, demonstrated that acute hematologic and 
GI toxicities developed more frequently in patients who re-
ceived monthly fluorouracil and cisplatin-based CCRT. A pro-
spective study of celecoxib in which the authors used weekly 
cisplatin chemotherapy at 40 mg/m2 also reported an acute 
toxicity profile similar to ours.18
In terms of the treatment response, disease-free and overall 
survival, using rofecoxib as a radiosensitizer did not improve 
the prognosis of patients with locally advanced cervical cancer 
in the present study. However, it is difficult to make a con-
clusion regarding the efficacy of rofecoxib as a radiosensitizer 
because of the retrospective nature of our analysis. A phase II 
trial of rofecoxib in the treatment of cervical dysplasia also 
demonstrated that regression rates in the rofecoxib and place-
bo arm were not significant.19 There have been no reports in-
dicating the efficacy of rofecoxib as a radiosensitizer in pa-
tients who received CCRT. Using celecoxib as a sensitizer, 24 
of 78 patients had treatment failure, and 18 of those experi-
enced loco-regional failure in the RTOG 0128 study.20 Another 
prospective study reported that 25 of 31 patients achieved a 
CR, and 5 of these developed recurrent disease.18 These pro-
spective studies using celecoxib as a radiosensitizer showed 
that celecoxib did not improve patient survival. 
There are several potential reasons why COX-2 inhibitors 
fail to improve patient survival and treatment results. Treatment 
using COX-2 inhibitors is a molecular target therapy. To eval-
uate the exact effects of COX-2 inhibitors, COX-2 expression 
needs to be measured in each patient, and it is preferable to re-
cruit patients with cancer that strongly expresses COX-2. 
Additionally, the optimal dose of COX-2 inhibitor needed to 
act as a radiosensitizer is not known, and there are no avail-
able data on changes of COX-2 expression in cervical cancer 
after drug treatment.
There are several limitations in the present study. First of all, 
this is a retrospective study. To examine the toxicity and effi-
cacy of rofecoxib as a radiosensitizer, a prospectively designed 
study would be more appropriate. The study population was 
heterogeneous in terms of disease stage compared with the 
small sample size. Finally, the toxicity induced by rofecoxib it-
self could not be examined due to study design. It is important 
to examine the adverse effects that might be aggravated by 
COX-2 inhibitor during CCRT, as well as the toxicity of rofe-
coxib itself.
Since it has been reported that COX-2 inhibitors lead to a 
significant reduction in the number of colorectal polyps in pa-
tients with familial adenomatous polyposis, several studies 
have been performed to evaluate the efficacy and toxicity of 
celecoxib in the treatment of uterine cervical cancer.17,18,20,21 
Celecoxib and rofecoxib were the first 2 COX-2 inhibitors ap-
proved by the US Food and Drug Administration. However, 
there have been no reports on the use of rofecoxib in the treat-
ment of cervical cancer. 
To the best of our knowledge, this is the first study to evaluate 
the acute toxicity and efficacy of rofecoxib as a radiosensitizer 
for chemoradiation in the treatment of locally advanced cer-
vical cancer. Notwithstanding the inherent drawbacks of a ret-
rospective analysis, our data indicate that using rofecoxib at 
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25 mg twice a day during CCRT does not affect the acute tox-
icities of CCRT. Although rofecoxib is considered a safe drug 
if used only during CCRT, its benefit as a radiosensitizer 
should be further evaluated by a prospective study.
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